Clinical Study

Oxaliplatin and Bolus-Modulated 5-Fluorouracil as a Second-Line Treatment for Advanced Pancreatic Cancer: Can Bolus Regimens Replace FOLFOX When Considered for Second Line?

Table 1

Patients’ characteristics.

CharacteristicsFLOX arm3-week arm value

Age
 Median 5654.45
 Range 44–6941–68
Gender
 Male 16 (67%)17 (71%).49
 Female 8 (33%)7 (29%).35
Disease at presentation
 Locally advanced15 (63%)14 (58%).44
 Metastatic 9 (37%)10 (42%).23
Site of metastases
 Liver 5 (21%)6 (25%).48
 Lung 1 (4%)1 (4%)
 LN2 (8%)2 (8%)
 Peritoneal 1 (4%)1 (4%)
 others
Previous surgery
 Palliative 5 (21%)4 (17%).3
 Radical 1 (4%)1 (4%)
 None
Prior chemotherapy
 Gemcitabine single agent14 (58%)16 (67%).23
 Gem + 5FU8 (34%)6 (25%).17
 Gem + Platinol2 (8%)2 (8%)
Response to prior therapy
 Partial response
 Stable disease2 (8%)3 (12.5%).12
 Progression 22 (92%)21 (87.5%).27
Presented symptoms
 Pain8 (34%)8 (34%)
 Weight loss20 (84%)20 (84%)